Latest Tni Biotech Inc (TNIB) Headlines The Brewer Group

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Tni Biotech Inc (TNIB) Headlines

The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG") a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB") (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.

TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC") that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.

TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
Marketwire - Tue Dec 03, 7:16AM CST
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.

Today's Small Cap Stocks in Focus - PFIE, AFFY and TNIB
ACCESSWIRE - Thu Nov 07, 5:37AM CST
Profire Energy, Inc. (OTC: PFIE), Affymax, Inc. (OTC: AFFY) and TNI BioTech, Inc. (PINK: TNIB) have been added to our watch list.

Micro-Cap Review Magazine Fall/Winter 2013 Issue Now Available on StockNewsNow.com and MicroCapReview.com
Marketwire - Tue Oct 15, 7:00AM CDT
SNN Incorporated, a global financial publishing, media, events, infotainment company, and publisher of the Micro-Cap Review Magazine and StockNewsNow.com, is pleased to announce that the Micro-Cap Review Magazine Fall/Winter 2013 Issue print and web version is now in distribution.

TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:

TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN") for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.

TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN") for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.

TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.

FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK® Phase III Study Design
ACCESSWIRE - Tue Jul 09, 8:24AM CDT
Bethesda, MD (eTeligis via ACCESSWIRE) - July 8, 2013 - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK® in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.

FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK[R] Phase III Study Design
ACCESSWIRE - Tue Jul 09, 7:20AM CDT
Bethesda, MD, July 9, 2013 - (eTeligis via Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK[R] in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.

TNI BioTech, Inc., Concludes Type C Meeting at the FDA
ACCESSWIRE - Mon Jul 01, 9:26AM CDT
BETHESDA, Md - (Eteligis via Accesswire ) -- TNI BioTech, Inc. ("TNIB", the "Company") (OTCQB: TNIB) announced today that it has a Type C Meeting with the FDA in Washington, D.C., to review the Company's Development Program for its Phase III Drug Candidate, Naltrexone HCL [Low Dose Naltrexone (LDN) IRT-103

TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
PR Newswire - Fri Jun 07, 11:34AM CDT
TNI BioTech, Inc. (TNIB, the "Company") (OTCQB: TNIB) announced today that effective as of the opening of business on Monday June 10, 2013, the Company will require the mandatory exchange of all existing common stock certificates issued with or under any prior CUSIP number for new stock certificates with the new CUSIP number 872608203.

TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
PR Newswire - Mon Jun 03, 7:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) announced today that Dr. Ronald Herberman, the Company's Senior Vice President and Chief Medical Officer, unexpectedly passed away over the weekend.

College of Pharmacy Partners With TNI BioTech to Develop New Drugs for Africa
Marketwire - Thu May 23, 8:56AM CDT
Howard University College of Pharmacy has signed a multi-year agreement with TNI BioTech, Inc. (OTCQB: TNIB), a Bethesda, Md., biotech firm that develops immunotherapy drugs to treat patients with chronic diseases, to assist in TNI BioTech's efforts to provide affordable health care and the development of pharmaceutical skills in Africa.

TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace
PR Newswire - Mon May 20, 7:15AM CDT
TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the OTC Markets' OTCQB marketplace under the ticker symbol "TNIB" commencing May 17, 2013. Investors will be able to view the real-time Level II stock quotes for TNIB at http://www.otcmarkets.com/stock/TNIB/quote.

TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events
PR Newswire - Thu May 16, 7:15AM CDT
TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows:

Biostax Corp. (BTAX) Stock Research Links

BTAX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 110

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 84

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 102

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 151

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 84

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 95

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 135

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 182

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Tools Revolutionizing Family Medicine Screening

Updated Category News Views 120

Innovative AI Tools Revolutionizing Family Medicine Screening Recent studies illustrate the integration of AI in detecting health issues within family medicine Research published in Annals of Family Medicine delves into how artificial intelligence and digital applications such as tablets are enhancing the detection of significant health conditions like dementia, heart...

Continue Reading
Infortar's Strategic Share Buyback on Nasdaq Tallinn

Updated Category News Views 168

Infortar's Share Buyback Strategy Aktsiaselts Infortar has taken a strategic step by acquiring its own shares on the Nasdaq Tallinn Stock Exchange during the early November period. This initiative reflects the company’s commitment to enhancing shareholder value and maintaining a robust market presence. Details of the Share Acquisition During the acquisition phase from...

Continue Reading
Garmin Ltd. Announces Upcoming Earnings Call for Investors

Updated Category News Views 41

Garmin Ltd. Schedules Third Quarter Earnings Call Garmin Ltd. (NYSE: GRMN) is preparing for its third quarter earnings conference call, inviting all shareholders and interested parties to join. The call is an important event where executives will discuss recent business performance and future strategies. It will take place on a Wednesday at 10:30 a.m. EDT, coinciding with...

Continue Reading
BMC Medical Co., Ltd. Celebrates New France Office Opening

Updated Category News Views 152

Exciting Times for BMC Medical Co., Ltd. with New Office Opening BMC Medical Co., Ltd. has recently marked an important milestone with the launch of its new office. This occasion not only establishes a foothold in the local area but also demonstrates the company's commitment to improving healthcare services throughout Europe. A Grand Opening Ceremony Celebrating Growth...

Continue Reading
TGH Burn Center Enhances Care Through TECO Partnership

Updated Category News Views 202

Transforming Burn Care at TGH Burn Center The TGH Burn Center, previously known as Tampa General Hospital's Burn Center, has entered into an exciting partnership with TECO that aims to significantly enhance patient care. This collaboration focuses on innovative treatment and state-of-the-art technology to ensure that those suffering from burn injuries receive the best...

Continue Reading